Hongyun Zhao
Overview
Explore the profile of Hongyun Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
4194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al.
Nat Med
. 2025 Mar;
PMID: 40082695
Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a...
2.
Ruan D, Huang W, Li Y, Zhao Y, Shi Y, Jia Y, et al.
Signal Transduct Target Ther
. 2025 Feb;
10(1):62.
PMID: 40016191
HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively targets vascular endothelial growth factor receptor-2, endothelial growth factor receptor, and fibroblast growth factor receptor 1-3....
3.
Wen E, Tian Y, Fang M, Zhang Y, Zhao H, Wang Z, et al.
ACS Appl Mater Interfaces
. 2025 Jan;
17(5):7521-7538.
PMID: 39854589
20% acute pancreatitis (AP) develops into severe AP (SAP), a global health crisis, with an increased mortality rate to 30%-50%. Mitochondrial damage and immune disorders are direct factors, which exacerbate...
4.
Zhou Q, Zhao H, Lu S, Cheng Y, Liu Y, Zhao M, et al.
Lancet Reg Health West Pac
. 2025 Jan;
53:101260.
PMID: 39759798
Lung cancer is the most prevalent malignant tumour in the Asia-Pacific region. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers. Among these, the rate of mutations...
5.
Argueta S, Wang Y, Zhao H, Diwanji N, Gorgievski M, Cochran E, et al.
Front Immunol
. 2024 Dec;
15:1501365.
PMID: 39735543
Introduction: The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of B cell malignancies has fueled the development of numerous cell therapies. However, these cell therapies...
6.
Liu J, Sun D, Xu S, Shen J, Ma W, Zhou H, et al.
Front Immunol
. 2024 Nov;
15:1485703.
PMID: 39569187
Purpose: Currently, chemoimmunotherapy is effective only in a subset of patients with advanced non-squamous non-small cell lung cancer. Robust biomarkers for predicting the efficacy of chemoimmunotherapy would be useful to...
7.
Zhao S, Zhou H, Yang N, Wang Z, Jin W, Ma Y, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39551469
Introduction: Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy,...
8.
Liu T, Chen X, Mo S, Zhou T, Ma W, Chen G, et al.
Transl Lung Cancer Res
. 2024 Oct;
13(9):2222-2235.
PMID: 39430332
Background: Lung large cell neuroendocrine carcinoma (LCNEC) is an aggressive disease with poor prognosis and short-term survival, which lacks effective prognostic indicators. The study aims to investigate the molecular subtypes...
9.
Zhang Y, Huang Y, Yang Y, Zhao Y, Zhou T, Chen G, et al.
Signal Transduct Target Ther
. 2024 Sep;
9(1):255.
PMID: 39327433
There is still room for improvement in first-line treatment of advanced small cell lung cancer (SCLC). This trial firstly investigated efficacy and safety of antiangiogenic therapy (surufatinib) (200 mg, qd,...
10.
Lin S, Zhou H, Chen G, Xue J, Liu Q, Li J, et al.
BMC Cancer
. 2024 Jul;
24(1):797.
PMID: 38961378
Purpose: Patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) have proven benefit from anti-programmed cell death 1 (anti-PD-1) monotherapy. Here, we retrospectively analyze the association of plasma Epstein-Barr virus (EBV)...